EP
FDMT icon

Essential Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Essential Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$43 Hold
3
– – ﹤0.01% 2779
2026
Q2 		$40 Sell
3
-101
-97% -$984 ﹤0.01% 2804
2026
Q1 		$968 Hold
104
– – ﹤0.01% 2257
2025
Q4 		$780 Hold
104
– – ﹤0.01% 2106
2025
Q3 		$904 Buy
104
+3
+3% +$18 ﹤0.01% 2049
2025
Q2 		$375 Buy
+101
New +$355 ﹤0.01% 1776

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM
PCFFS
Pacific Center for Financial Services San Ramon, California $477M AUM 12.74% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's FDMT Position: Q3 2026 in Review

Essential Partners held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 3 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

Essential Partners first reported a position in FDMT in Q2 2025 and has held it in 6 quarters since. The position peaked at $968 in Q1 2026. 11 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Essential Partners held 3 shares of 4D Molecular Therapeutics worth $43 as of Q3 2026.
  • Essential Partners left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2779 holding.
  • Essential Partners first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's 4D Molecular Therapeutics position peaked at $968 in Q1 2026.
  • 11 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.